Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802151 | 0.87 | BRD4 (0.44) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL31560951 | 0.86 | BRD4 (0.43) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17331932 | 0.86 | BRD4 (0.43) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25353014 | 0.86 | BRD4 (0.43) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4169754 | 0.86 | BRD4 (0.43) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16868358 | 0.82 | HPGD (0.43) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16658367 | 0.82 | EPHX2 (0.47) | BRD4KEAP1KIF11ACLY | |
| SCHEMBL12811024 | 0.79 | PTGS1 (0.57) | KEAP1ALDH1A1SMN1; SMN2LMNAKIF11 | |
| SCHEMBL30023958 | 0.79 | PTGS1 (0.57) | KEAP1ALDH1A1SMN1; SMN2LMNAKIF11 | |
| SCHEMBL20782063 | 0.78 | ALDH1A1 (0.40) | BRD4KEAP1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12054480-B2 | Compounds for treating cannabinoid toxicity and acute cannabinoid overdose | MAKSCIENTIFIC, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-2877176-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PF MEDICAMENT (FR) | 2017-04-26 | — | — | EP | disclosed |
| US-9428510-B2 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk | PIERRE FABRE MEDICAMENT (FR) | 2016-08-30 | — | — | US | disclosed |
| US-9381195-B2 | Derivatives of azaindazole or diazaindazole type for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2016-07-05 | — | — | US | disclosed |
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | PIERRE FABRE MEDICAMENT (FR) | 2015-09-24 | — | — | US | disclosed |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2015-07-09 | — | — | US | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
| EP-1649849-A2 | Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. | Aventis Pharma S.A. (FR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006040464-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N-(1-BENZHYDRYL-AZETIDIN-3-YL)-N-PHENYL-METHYLSULPHONAMIDE | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040465-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | disclosed |
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2004-10-21 | — | — | US | disclosed |
| EP-1423145-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | Aventis Pharma S.A. (FR) | 2004-06-02 | — | — | EP | disclosed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | disclosed |
| WO-2003020314-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | AVENTIS PHARMA S.A. (FR) | 2003-03-13 | — | — | WO | disclosed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | BRD4 938/4885KEAP1 1482/4885ALDH1A1 2782/4885 |
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | TTK, NTRK1, NTRK3 | BRD4 308/4885KEAP1 3657/4885ALDH1A1 3886/4885 |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | BRD4 749/4885KEAP1 920/4885ALDH1A1 2415/4885 |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | SCN3A, ACHE, QDPR | BRD4 1509/4885KEAP1 1769/4885ALDH1A1 998/4885 |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | BRD4 938/4885KEAP1 1482/4885ALDH1A1 2782/4885 |
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | BRD4 1004/4885KEAP1 2460/4885ALDH1A1 2669/4885 |
| US-12054480-B2 | Compounds for treating cannabinoid toxicity and acute cannabinoid overdose | CNR1, CNR2, OPRM1 | BRD4 938/4885KEAP1 1482/4885ALDH1A1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.